AU2021369193A1 - Compounds,compositions and methods of use to treat spinal fusions - Google Patents

Compounds,compositions and methods of use to treat spinal fusions Download PDF

Info

Publication number
AU2021369193A1
AU2021369193A1 AU2021369193A AU2021369193A AU2021369193A1 AU 2021369193 A1 AU2021369193 A1 AU 2021369193A1 AU 2021369193 A AU2021369193 A AU 2021369193A AU 2021369193 A AU2021369193 A AU 2021369193A AU 2021369193 A1 AU2021369193 A1 AU 2021369193A1
Authority
AU
Australia
Prior art keywords
amino acid
acid residues
sequence identity
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021369193A
Other languages
English (en)
Other versions
AU2021369193A9 (en
Inventor
Philip S. Low
Stewart LOW
Jeffery Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of AU2021369193A1 publication Critical patent/AU2021369193A1/en
Publication of AU2021369193A9 publication Critical patent/AU2021369193A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2021369193A 2020-10-26 2021-08-26 Compounds,compositions and methods of use to treat spinal fusions Pending AU2021369193A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063105678P 2020-10-26 2020-10-26
US63/105,678 2020-10-26
US202163193753P 2021-05-27 2021-05-27
US63/193,753 2021-05-27
PCT/US2021/047827 WO2022093374A1 (en) 2020-10-26 2021-08-26 Compounds,compositions and methods of use to treat spinal fusions

Publications (2)

Publication Number Publication Date
AU2021369193A1 true AU2021369193A1 (en) 2023-06-01
AU2021369193A9 AU2021369193A9 (en) 2024-10-10

Family

ID=81383097

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021369193A Pending AU2021369193A1 (en) 2020-10-26 2021-08-26 Compounds,compositions and methods of use to treat spinal fusions

Country Status (7)

Country Link
US (1) US20230390363A1 (https=)
EP (1) EP4232075A4 (https=)
JP (1) JP2023547889A (https=)
AU (1) AU2021369193A1 (https=)
CA (1) CA3196688A1 (https=)
MX (1) MX2023004829A (https=)
WO (1) WO2022093374A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019232285A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
WO2022093373A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat bone fractures
EP4719459A1 (en) * 2023-06-01 2026-04-08 Radius Health, Inc. Methods for identification and quantitation of abaloparatide and related peptide impurities

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102616A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
EP3765488A1 (en) * 2018-03-12 2021-01-20 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of pthrp analogue
WO2019232285A1 (en) * 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
WO2022093373A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat bone fractures

Also Published As

Publication number Publication date
WO2022093374A1 (en) 2022-05-05
MX2023004829A (es) 2023-07-18
CA3196688A1 (en) 2022-05-05
WO2022093374A8 (en) 2022-09-29
JP2023547889A (ja) 2023-11-14
EP4232075A4 (en) 2024-12-18
US20230390363A1 (en) 2023-12-07
EP4232075A1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
JP7418527B2 (ja) 制御放出ｐｔｈ化合物の投薬レジメン
JP2023029957A (ja) 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生
US20230390363A1 (en) Compounds, Compositions and Methods of Use to Treat Spinal Fusions
US20230399374A1 (en) Compounds, Compositions and Methods of Use to Treat Bone Fractures
JP2024037994A (ja) 放出制御ｐｔｈ化合物の漸増用量設定
EP2717902B1 (en) Use of modified vasoactive intestinal peptides in the treatment of hypertension
US20210206820A1 (en) Targeting anabolic drugs for accelerated fracture repair
EP3498291A1 (en) Pharmaceutical composition and biomaterial comprising fusion peptide having parathyroid hormone (pth) conjugated with peptide selective for bone tissue
KR101108354B1 (ko) Ｐｔｈ 수용체 조절제로서의 페길화된 ｐｔｈ 및 그의 용도
KR20180135016A (ko) 페길화 생활성 펩타이드 및 그의 용도
US10947285B2 (en) Compounds, compositions and uses thereof for improvement of bone disorders
JP5529014B2 (ja) 部位特異的なペグ化をされた直鎖状のサケカルシトニン類似体
CN116710068A (zh) 用于治疗脊柱融合的化合物、组合物和方法
CN116801900A (zh) 用于治疗骨折的化合物、组合物和使用方法
WO2001007065B1 (en) PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES
JPH07258110A (ja) 骨疾患治療剤

Legal Events

Date Code Title Description
SREP Specification republished